Xinke Wang

Dr. Xinke Wang

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
QLQingyuan Li
Qingyuan Li
QLQiuhua Lai
Qiuhua Lai
CHChengcheng He
Chengcheng He
YFYuxin Fang
Yuxin Fang
QYQun Yan
Qun Yan
SLside liu
side liu
Runt-related transcription factor 1 (RUNX1) plays the roles of an oncogene and an anti-oncogene in epithelial tumours, and abnormally elevated RUNX1 has been suggested to contribute to the carcinogenesis of colorectal cancer (CRC). However, the mechanism remains unclear. The expression of RUNX1 in CRC and normal tissues was detected by real-time quantitative PCR and Western blotting. The effect of RUNX1 on CRC migration and invasion was conducted by functional experiments in vitro and in vivo. Chromatin Immunoprecipitation assay verified the direct regulation of RUNX1 on the promoter of the KIT, which leads to the activation of Wnt/β-catenin signaling. RUNX1 expression is upregulated in CRC tissues. Upregulated RUNX1 promotes cell metastasis and epithelial to mesenchymal transition (EMT) of CRC both in vitro and in vivo. Furthermore, RUNX1 can activate Wnt/β-catenin signalling in CRC cells by directly interacting with β-catenin and targeting the promoter and enhancer regions of KIT to promote KIT transcription. These observations demonstrate that RUNX1 upregulation is a common event in CRC specimens and is closely correlated with cancer metastasis and that RUNX1 promotes EMT of CRC cells by activating Wnt/β-catenin signalling. Moreover, RUNX1 is regulated by Wnt/β-catenin. Our findings first demonstrate that RUNX1 promotes CRC metastasis by activating the Wnt/β-catenin signalling pathway and EMT.

31 March 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ZLZhixian Lan
Zhixian Lan
XYXiang Yao
Xiang Yao
KSKangyue Sun
Kangyue Sun
ALAimin Li
Aimin Li
SLside liu
side liu
XWXinke Wang
Xinke Wang
Background: Small nucleolar RNA host gene 6 (SNHG6) acts as a carcinogenic gene in colorectal cancer (CRC). However, previous studies on the mechanism by which long non-coding RNA (lncRNA) SNHG6 exerts its carcinogenic effect in CRC have not involved the direct interaction between SNHG6 and proteins, which is a very important carcinogenic mechanism of lncRNAs. Hence, our study conducted a comprehensive RNA-binding proteins–mass spectrometry (ChIRP–MS) analysis on SNHG6 to further explore its carcinogenic mechanism in CRC. Methods: Proteins that interact with SNHG6 were found using ChIRP–MS analysis and were used to construct the protein–protein interactive (PPI) network using STRING, while the core module of the PPI network was identified using the MCODE plugin in Cytoscape. Pathway enrichment analyses, using WebGestalt, were performed on proteins and RNAs that were found to be associated with the expression of SNHG6 or which directly interacted with SNHG6. Finally, CatRAPID, miRbase, and TargetScanHuman were used to identify the sites of interaction between SNHG6, heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1), and pyruvate kinase M (PKM) mRNA. Results: The expression of SNHG6 in CRC was found to be higher than that of normal tissues and was positively correlated with a poor prognosis (p < 0.05). A total of 467 proteins that are able to interact with SNHG6 in CRC cells were identified using ChIRP–MS analysis and were used to create a PPI network, within which a core module composed of 44 proteins that performed the function of splicing mRNA, including hnRNPA1, was found to be positively correlated with SNHG6 (p < 0.05). The results of the pathway enrichment analyses suggested that SNHG6 played an important role in the metabolism of CRC by affecting the expression of PKM and SNHG6. The increase in the ratio of PKM2/PKM1 was proven using quantitative real-time polymerase chain reaction analysis. Further exploration suggested that SNHG6 could bind to hnRNPA1 and PKM. Conclusion: SNHG6 was found to be able to target the mRNA of PKM as well as induce hnRNPA1 to specifically splice PKM mRNA, which increased the proportion of PKM2/PKM1, which may be an important carcinogenic mechanism in CRC that proceeds through the enhancement of aerobic glycolysis in CRC cells.

2 April 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
XYXiang Yao
Xiang Yao
ZLZhixian Lan
Zhixian Lan
QLQiuhua Lai
Qiuhua Lai
ALAimin Li
Aimin Li
SLSide Liu
Side Liu
XWXinke Wang
Xinke Wang

6 June 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ZDZhuoyu Ding
Zhuoyu Ding
YWYiyi Wei
Yiyi Wei
JDJingping Dai
Jingping Dai
CPChaomin Pan
Chaomin Pan
LYLi Yang
Li Yang
XWXinke Wang
Xinke Wang
Background: Several studies have demonstrated a strong correlation between impaired Succinate dehydrogenase (SDH) function and the advancement of tumors. As a subunit of SDH, succinate dehydrogenase complex subunit C (SDHC) has been revealed to play tumor suppressive roles in several cancers, while its specific role in colorectal cancer (CRC) still needs further investigation. Methods: Online database were utilized to investigate the expression of SDHC in colorectal cancer and to assess its correlation with patient prognosis. Cell metastasis was assessed using transwell and wound healing assays, while tumor metastasis was studied in a nude mice model in vivo. Drug screening and RNA sequencing were carried out to reveal the tumor suppressor mechanism of SDHC. Triglycerides, neutral lipids and fatty acid oxidation were measured using the Triglyceride Assay Kit, BODIPY 493/503 and Colorimetric Fatty Acid Oxidation Rate Assay Kit, respectively. The expression levels of enzymes involved in fatty acid metabolism and the PI3K/AKT signaling pathway were determined by quantitative real-time PCR and western blot. Results: Downregulation of SDHC was found to be closely associated with a poor prognosis in CRC. SDHC knockdown promoted CRC metastasis both in vitro and in vivo. Through drug screening and Gene set enrichment analysis, it was discovered that SDHC downregulation was positively associated with the fatty acid metabolism pathways significantly. The effects of SDHC silencing on metastasis were reversed when fatty acid synthesis was blocked. Subsequent experiments revealed that SDHC silencing activated the PI3K/AKT signaling axis, leading to lipid accumulation by upregulating the expression of aldehyde dehydrogenase 3 family member A2 (ALDH3A2) and reduction of fatty acid oxidation rate by suppressing the expression of acyl-coenzyme A oxidase 1 (ACOX1) and carnitine palmitoyltransferase 1A (CPT1A). Conclusions: SDHC deficiency could potentially enhance CRC metastasis by modulating the PI3K/AKT pathways and reprogramming lipid metabolism.

1 January 2024 in International Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
CPChaomin Pan
Chaomin Pan
JDJingping Dai
Jingping Dai
YWYiyi Wei
Yiyi Wei
LYLi Yang
Li Yang
ZDZhuoyu Ding
Zhuoyu Ding
JHJuan He
Juan He
Purpose: Matrix metalloproteinase-11 (MMP11), which belongs to the stromelysin subgroup, has been reported to play a role in the progression of colorectal cancer (CRC). However, the significance of MMP11 in the tumor microenvironment, immune/stromal cells, and its mechanism in CRC remain unclear.

24 February 2026 in PeerJ
Verified
Journal Article
Open access
PDF file
SDSiyu Duan
Siyu Duan
YWYiyi Wei
Yiyi Wei
ZDZhuoyu Ding
Zhuoyu Ding
CPChaomin Pan
Chaomin Pan
LYLi Yang
Li Yang
XWXinke Wang
Xinke Wang
Background: The metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common causes of chronic and abnormal liver function tests globally. The relationship between metabolic MASLD and gastrointestinal tumors (GI) remains controversial. Methodology: We conducted a systematic review based on a protocol registered with PROSPERO (CRD42024590389). PubMed, Cochrane Library, Web of Science, and Embase were systematically searched until November 2025, Quality assessment and data extraction were performed by two investigators, and the hazard ratios and their corresponding 95% confidence intervals were combined using Stata for data analysis. Results: A total of 29 studies were included, we found that MASLD were related to colorectal polyps ( I 2 = 62.7, HR = 1.42, 95% CI [1.22–1.66]), colorectal cancer ( I 2 = 82.8%, HR = 1.22, 95% CI [1.16–1.29]), p < 0.001) and esophagus cancer ( I 2 =88.4, HR = 1.14, 95% CI [1.05–1.24], p < 0.001), gastric cancer ( I 2 = 88, HR = 1.18, 95% CI [1.1–1.26]), cholangiocarcinoma ( I 2 = 73.7, HR = 1.26, 95% CI [1.1 7–1. 36], P < 0.001) and gallbladder cancer ( I 2 = 56.1, HR = 1.41, 95% CI [1.03–1.92], P < 0.001). Factors like follow-up time, study methods and countries contributed to heterogeneity of studies. Lastly, incidence rates (IR) and prognosis of GI cancer in patients with MASLD were highly correlated. Conclusion: We conclude that there is a significant association and prognosis between MASLD and gastrointestinal tumors. Further studies should focus on prospective studies and mechanistic insights.